News | September 28, 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In India, almost all approved vaccines are packed in FIOLAX glass made by SCHOTT
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
_256_384.jpg)
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
The country has constantly worked with the spirit of public-private partnership
At the latest Indian Pharma Post E-Conference, leading experts identified faster regulatory approvals, infrastructure, digital innovation, investigator training, and public trust as critical pillars
Subscribe To Our Newsletter & Stay Updated
